Rigel Pharmaceuticals reported $39.45M in Debt for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Agenus AGEN:US USD 13.16M 299K
Amgen AMGN:US USD 38.94B 241M
Astrazeneca AZN:US USD 29.23B 67M
AstraZeneca AZN:LN USD 29.23B 67M
Biomarin Pharmaceutical BMRN:US USD 1.09B 3.46M
Bristol Myers Squibb BMY:US USD 39.32B 222M
Daiichi Sankyo 4568:JP JPY 143.18B 93M
Halozyme Therapeutics HALO:US USD 1.51B 1.63M
Heron Therapeutics HRTX:US USD 149.23M 52K
Intrexon XON:US USD 43.22M 38.85M
Karyopharm Therapeutics KPTI:US USD 302.82M 69K
Ligand Pharmaceuticals LGND:US USD 76.74M 92K
Neurocrine Biosciences NBIX:US USD 169.4M 200K
Regeneron Pharmaceuticals REGN:US USD 2.7B 300K
Rigel Pharmaceuticals RIGL:US USD 39.45M 20K
Veracyte VCYT:US USD 400K 1.29M